secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001213900-24-027960
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio reports FY2023 net loss of $30.0M; pipeline updates for XPro, INKmune
--------------------------------------------------------------------------------

- Net loss for FY2023 was $30.0M, up from $27.3M in FY2022; R&D spend rose to $20.3M.
- Cash and equivalents at Dec 31, 2023: $35.8M; shares outstanding ~18.0M as of Mar 28, 2024.
- XPro AD02 Alzheimer's trial on track for mid-2024 enrollment completion; top-line data ~6 months later.
- Phase I/II INKmune mCRPC trial enrolled first patient Dec 2023; cohort 2 to open after DSMC review in mid-April.
- Company winding down AML program to focus on prostate cancer and other solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/0001213900-24-027960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024027960/ea0202918-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-027960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer